| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-07-4586 |
| P698 | PubMed publication ID | 18559583 |
| P2093 | author name string | Robert Carr | |
| Gary Gordon | |||
| Vincent Giranda | |||
| Terri Leahy | |||
| Helen Eliopoulos | |||
| Rita Tiehen | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3683-3688 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Phase 0 trials: an industry perspective | |
| P478 | volume | 14 |
| Q95851906 | A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug |
| Q36732115 | Designing phase 0 cancer clinical trials |
| Q36853927 | Early-Phase Development of Cancer Prevention Agents: Challenges and Opportunities |
| Q36732058 | Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient |
| Q38100299 | PARP inhibitors: polypharmacology versus selective inhibition |
| Q37358487 | Phase 0 clinical studies in oncology |
| Q34941964 | Phase 0 clinical trials in oncology new drug development |
| Q84400479 | Phase 0 exploratory clinical trials: literature review 2006-2009 |
| Q39934032 | Role of Phase 0 trials in drug development |
Search more.